DeiPharma Group, a privately owned biopharmaceutical company based in Matugga, Wakiso district is set to provide over 40,000 direct jobs and 10,000 indirect jobs in related sectors, particularly agriculture, once fully operational.

The Chief Executive Officer of DeiPharma Group, Matthias Magoola, who was speaking during a media briefing in Matugga on January 16, 2025, mentioned that once completed, the hub, which spans 150 acres will be Uganda’s first research-focused biotechnology and pharmaceuticals company.

“It is expected to significantly reduce unemployment rates, provide livelihoods for many families, and enhance community welfare,” he said.

According to him, the facility is not solely focused on job creation but also demonstrates a commitment to nurturing local innovation.

“By utilizing advanced technologies like mRNA and gene therapy, Dei Biopharma is positioning Uganda as a leader in biotechnology and pharmaceuticals,” he added.

Mathias lauded the Ugandan government for its investment of Shs 723 billion towards the construction of the new Dei-Biopharma hub.

He noted that this investment will empower local scientists and researchers, reducing reliance on imported medicines and promoting a self-sustaining healthcare ecosystem.

Dei BioPharma’s commitment to high-quality production has attracted international attention, including praise from the World Health Organization (WHO), which recognized the facility as a vital hub for Africa’s response to health crises like COVID-19.

The creation of Dei Biopharma is in line with Uganda’s overarching goals of industrialization and economic independence.

The expected expansion of the pharmaceutical sector is likely to attract additional investments, generating a ripple effect that will benefit various industries throughout Uganda.